Can a single drug free patients from insulin after immunotherapy?
NCT ID NCT07257068
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This pilot study tests whether the drug infliximab can safely reverse insulin dependence in people who developed diabetes after taking checkpoint inhibitor cancer therapy. About 14 participants will receive the drug and be monitored for side effects and changes in their need for insulin. The goal is to see if early treatment can help the pancreas recover and reduce or eliminate the need for daily insulin shots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHECKPOINT INHIBITOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can the dirt under our feet shape the bacteria in our gut?
- New pill may help diabetics fast safely during ramadan
- New ventilation technique may help patients breathe easier after robotic surgery
- Could your sleep and meal timing in early pregnancy predict diabetes?
- Heart bypass drug showdown: which pill keeps arteries open longest?
- Can a daily probiotic change your gut and brain? new study investigates